Stem cell play­er Vi­a­Cyte ex­pands col­lab­o­ra­tion with Gore to de­vel­op sub­cu­ta­neous di­a­betes treat­ment

Long­time stem cell play­er Vi­a­Cyte has teamed up with a ma­te­ri­als sci­ence com­pa­ny in an ef­fort to solve im­muno­sup­pres­sion chal­lenges and ad­vance its type 1 di­a­betes treat­ments.

Ex­pand­ing on an ex­ist­ing col­lab­o­ra­tion, Vi­a­Cyte and W.L. Gore have agreed to com­bine the biotech’s PEC-En­cap can­di­date with a Gore-pro­duced mem­brane in what they hope will elim­i­nate the need for im­muno­sup­pres­sive drugs. Such treat­ments have cre­at­ed for­eign body re­spons­es in the past, and stamp­ing these re­ac­tions out is the main goal, Vi­a­Cyte CEO Paul Laikind said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER